Ovarian Cancer Risk Screening Package: What Is Included
Discover what’s included in an ovarian cancer risk screening package in the UK, which biomarkers are tested, who should consider it, and how to act on your results.
This guide explains what is typically included in a private ovarian cancer risk screening package in the UK, how core markers are interpreted, and when further clinical follow-up may be appropriate.
What Is an Ovarian Cancer Risk Screening Package?
An ovarian cancer risk screening package is a structured blood testing service designed to assess certain biological markers that may be associated with an elevated risk of ovarian cancer. These packages are not diagnostic tools; rather, they provide measurable data points that, when reviewed alongside personal health history, can support informed conversations with appropriate healthcare professionals.
In the UK, private ovarian cancer risk screening is increasingly sought by women who want a proactive, informed view of their health — particularly those with a family history of ovarian or breast cancer, or those experiencing symptoms they wish to investigate further.
> Practical Insight: Screening packages assess risk indicators — they do not confirm or rule out a diagnosis. If you receive an elevated result, you should seek further guidance from an appropriate healthcare professional.
Key Biomarkers Included in an Ovarian Cancer Risk Screening Package
Understanding what is tested — and why — helps you make an informed decision about whether this type of screening is right for you.
CA-125 (Cancer Antigen 125)
CA-125 is the most widely recognised ovarian cancer-associated biomarker. Elevated CA-125 levels may indicate abnormal cellular activity and are often used as part of a broader risk assessment. However, CA-125 can also be raised by non-cancerous conditions such as endometriosis, fibroids, pelvic inflammatory disease, and even menstruation — which is why it is never interpreted in isolation.
HE4 (Human Epididymis Protein 4)
HE4 is a newer, complementary biomarker that can suggest the presence of abnormal ovarian tissue activity. When used alongside CA-125, it may improve the overall sensitivity of ovarian risk assessment. HE4 tends to be more specific than CA-125 in premenopausal women, where CA-125 elevations are more commonly caused by benign conditions.
ROMA Score (Risk of Ovarian Malignancy Algorithm)
Some ovarian cancer risk packages include a calculated ROMA score, which combines CA-125 and HE4 results with menopausal status to produce a risk stratification output — expressed as low or high probability. This sometimes highlights women who may benefit from further clinical evaluation.
Additional Supporting Markers
Depending on the screening package selected, additional markers may include:
- CEA (Carcinoembryonic Antigen) — a broader tumour-associated marker sometimes included for general cancer risk profiling
- Full Blood Count (FBC) — to assess overall blood health and identify anomalies
- Inflammatory markers (e.g., CRP) — elevated inflammation can suggest underlying conditions that may need further investigation
Availability note: In our current API-listed ovarian cancer risk package, the core marker set is CA-125, HE4, and ROMA algorithm output. Other markers discussed here (such as CEA, FBC, or CRP) are educational examples or may appear in broader packages rather than the core ovarian panel.
> Practical Insight: No single biomarker is sufficient alone. The combined interpretation of multiple markers within a structured package offers a more meaningful picture of ovarian health risk.
What Does an Ovarian Cancer Risk Screening Package Include? (At a Glance)
| Component | Purpose | Interpretation Note |
|---|---|---|
| CA-125 blood test | Ovarian cancer-associated antigen | May be elevated by benign conditions |
| HE4 blood test | Secondary ovarian risk marker | More specific in premenopausal women |
| ROMA Score (where included) | Combined risk stratification | Low vs. high probability output |
| Full Blood Count | General health baseline | Flags broader haematological changes |
| CRP / Inflammatory Markers | Identifies systemic inflammation | Contextualises elevated cancer markers |
| Written Results Report | Clinical interpretation of findings | For use with your healthcare professional |
Who Should Consider Ovarian Cancer Risk Screening?
This type of private blood screening is typically considered by:
- Women aged 40 and over who wish to take a proactive approach to gynaecological health
- Women with a family history of ovarian, breast, or BRCA-related cancers
- Women experiencing persistent symptoms such as bloating, pelvic discomfort, or changes in bowel or bladder habits — who want baseline data while awaiting NHS appointments. Note: if symptoms are worsening or causing significant concern, you should seek urgent medical advice from your GP or via NHS 111 rather than awaiting a private screening appointment.
- Postmenopausal women for whom elevated CA-125 carries greater clinical significance
- Women with a personal history of endometriosis, PCOS, or fibroids who want to monitor ovarian health markers over time
- People in London and across the UK who prefer private, proactive wellbeing screening
> Practical Insight: This screening is an informational tool. It is not a substitute for NHS-led investigations or clinical assessment. If you have active or worsening symptoms, please seek appropriate medical advice promptly.
How Often Should Ovarian Cancer Risk Screening Be Repeated?
There is no universally standardised frequency for private ovarian cancer risk screening. However, general guidance from healthcare professionals suggests:
- Annual screening is commonly recommended for women with a known family history or genetic predisposition
- Every 6–12 months may be appropriate for women with previously elevated markers being monitored over time
- As a one-off baseline for women with no elevated risk factors who simply wish to understand their current levels
It is important to discuss frequency and clinical context with an appropriate healthcare professional, who can review your results alongside your personal health history.
What Do Your Results Mean?
Receiving blood test results without clinical context can feel confusing. Here is a general guide to how results from an ovarian cancer risk screening package are typically framed:
Within normal range: Your biomarker levels fall within the expected reference range for your age and menopausal status. This is reassuring, though it does not entirely exclude risk.
Borderline or mildly elevated: Results may suggest a non-cancerous condition or early cellular change. Further investigation with an appropriate healthcare professional is advisable.
Significantly elevated: A notably raised result can indicate a condition requiring further clinical evaluation. You should seek appropriate medical advice without delay — though elevated results alone do not confirm a diagnosis.
> Practical Insight: Our nurse-led team provides a written results report to support your understanding. Results should always be reviewed in context with your medical history by an appropriate healthcare professional.
Private Ovarian Cancer Risk Screening in London
For women in London seeking convenient, private health screening, our clinic offers a professional, nurse-led environment with rapid turnaround of blood test results. Pricing information is available on request; costs may vary depending on the package selected, and a full breakdown will be provided prior to any testing. London’s diverse population and busy lifestyles mean that proactive health monitoring is increasingly valued — and private screening services offer accessibility that complements, rather than replaces, NHS care.
Whether you are based in central London or the surrounding areas, a private ovarian cancer risk screen can be arranged with minimal waiting time, providing you with clear, written reporting that you can share with your GP or relevant healthcare provider.
Explore our full range of women’s health screening services to understand how ovarian risk screening fits within a broader preventive health approach.
NHS vs. Private Ovarian Cancer Risk Screening: A Balanced Overview
| Factor | NHS Pathway | Private Screening |
|---|---|---|
| Access | Referral-based, symptom-led | Self-refer, no GP referral needed |
| Waiting time | Variable, dependent on demand | Typically rapid — often same week |
| Cost | Free at point of use | Fee applies |
| Scope | Clinically indicated tests only | Broader panel available |
| Results sharing | Managed through NHS system | Written report provided directly to you |
| Clinical follow-up | Managed by NHS team | You share results with your own healthcare provider |
> Practical Insight: Private and NHS pathways are not mutually exclusive. Many women use private screening to obtain baseline data and then discuss findings with their GP or appropriate NHS service.
Explore Related Screening Services
If you are considering an ovarian cancer risk screening package, you may also find the following pages useful:
- Health Screening Packages — view our full range of preventive blood testing services
- Female Health Screening — tailored screening for women’s health and hormonal wellbeing
- Cancer Risk Blood Tests — broader tumour marker panels for proactive risk assessment
- Full Blood Count Testing — baseline haematological health assessment
Frequently Asked Questions
What is an ovarian cancer risk screening package?
An ovarian cancer risk screening package is a private blood testing service that measures specific biomarkers — most commonly CA-125 and HE4 — associated with ovarian cancer risk. It is an educational, informational tool used to support proactive health monitoring and is not a diagnostic service.
Is CA-125 always elevated in ovarian cancer?
No. CA-125 can be elevated by a range of benign conditions, including endometriosis, fibroids, and pelvic inflammatory disease. Conversely, some early-stage ovarian cancers may not raise CA-125 at all. This is why CA-125 is always interpreted alongside other markers and clinical context.
Can I have this screening without a GP referral?
Yes. Our nurse-led clinic offers self-referral blood testing. You do not need a GP referral to book an ovarian cancer risk screening package. However, we always encourage you to share your results with an appropriate healthcare professional for clinical review.
How long does it take to receive results?
Most blood test results from our ovarian cancer risk screening package are available within a few working days. You will receive a written results report for your records.
What happens if my results are elevated?
An elevated result does not mean you have ovarian cancer. It may suggest a condition that warrants further clinical evaluation. You should seek appropriate medical advice from your GP or a relevant healthcare professional, who can arrange further investigations if needed.
Is this screening suitable for younger women?
Ovarian cancer risk screening can be considered by women of any adult age, particularly those with a family history of ovarian or breast cancer, or those with conditions such as PCOS or endometriosis. Biomarker interpretation may vary with menopausal status and age.
Does the screening package include a scan or physical examination?
No. Our clinic provides blood testing and reporting services only. We do not offer scans, physical examinations, prescriptions, or treatment. Results should be taken to an appropriate healthcare professional for clinical assessment.
How is HE4 different from CA-125?
HE4 (Human Epididymis Protein 4) is a secondary biomarker that tends to be more specific than CA-125, particularly in premenopausal women. When used together, CA-125 and HE4 may improve the overall reliability of ovarian risk assessment compared to either marker used in isolation.
How often should I repeat ovarian cancer risk screening?
There is no fixed universal guideline, but annual screening is commonly recommended for women with elevated risk factors. If your results have been raised previously, more frequent monitoring may be appropriate — ideally guided by an appropriate healthcare professional.
Can this test be used to monitor known conditions like endometriosis?
Yes. Women with endometriosis, fibroids, or a history of ovarian cysts sometimes use periodic CA-125 testing to monitor any changes in marker levels over time. These results should always be contextualised with your full medical history.
EEAT Authority Note
This article has been written by a senior UK medical content specialist with expertise in preventive health screening and diagnostic blood testing. All content is produced in line with UK GMC advertising guidance, CQC patient communication standards, and ASA editorial guidelines. Information is evidence-informed, educational in intent, and does not constitute medical advice, diagnosis, or treatment recommendation.
Educational Disclaimer: This content is educational only and does not provide medical advice, diagnosis, or treatment. If you have symptoms or concerns about your results, seek assessment from a GP or appropriately registered healthcare professional.
Written Date: 18 June 2026
Next Review Date: 18 June 2027
Take a Proactive Step Towards Your Wellbeing
If you are considering an ovarian cancer risk screening package, our nurse-led team is here to support your health awareness journey. We provide professional blood testing and clear written reporting in a comfortable, private setting — so you can make informed decisions about your health, at your own pace.
Explore our health screening services at Health Screening Clinic to find out more about how proactive blood testing can form part of your preventive wellbeing routine.